Similar articles

• The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

  Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ. Vedder MM, et al. Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26. Eur Urol. 2014. PMID: 25168616 Free PMC article.
• 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.

  McDonald ML, Parsons JK. McDonald ML, et al. Urol Clin North Am. 2016 Feb;43(1):39-46. doi: 10.1016/j.ucl.2015.08.004. Urol Clin North Am. 2016. PMID: 26614027 Review.
• Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.

  Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H. Kim EH, et al. J Urol. 2017 Apr;197(4):1041-1047. doi: 10.1016/j.juro.2016.10.089. Epub 2016 Nov 1. J Urol. 2017. PMID: 27810449 Free PMC article.
• Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.

  Rubio-Briones J, Casanova J, Dumont R, Rubio L, Fernandez-Serra A, Casanova-Salas I, Domínguez-Escrig J, Ramírez-Backhaus M, Collado A, Gómez-Ferrer A, Iborra I, Monrós JL, Ricós JV, Solsona E, Salas D, Martínez F, Lopez-Guerrero JA. Rubio-Briones J, et al. Actas Urol Esp. 2014 May;38(4):217-23. doi: 10.1016/j.acuro.2013.09.007. Epub 2013 Oct 27. Actas Urol Esp. 2014. PMID: 24169211 Clinical Trial. English, Spanish.
• [PSA and blood test diagnostics of prostate cancer].

  Seikkula H, Pettersson K, Boström PJ. Seikkula H, et al. Duodecim. 2015;131(17):1547-52. Duodecim. 2015. PMID: 26548101 Review. Finnish.